Ranbaxy starts phase III study of anti-malaria drug
Ranbaxy starts phase III study of anti-malaria drug

Ranbaxy Laboratories announced that its new anti-malarial combination drug is now undergoing final stage of development. In its press-release, the company said that the drug is targeted at patients in developing countries with the aim of significantly improving upon the conventional options available for the treatment of P falciparum malaria.

whatsapp--v1